$MILV is stalking the land of silver now as it takes over penny land this week.
QUESTIONS (answers below)
A) Who does CCA have a contract to License their technology to?
B) What has CCA license to the University of Pennsylvania?
C) What does the CCA's management believes their technology could be used for with other pharmaceutical products?
D) What type of medical conditions do they believe their technology could be used to treat?
E) Who does CCA have a patent assigned from?
F) What Vitamin was being used by the writer of the patent as the bases of his encapsulated delivery system?
G) What does this paper have to do with the above?
Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model https://clincancerres.aacrjournals.org/content/clincanres/early/2018/03/07/1078-0432.CCR-17-3811.full.pdf
A) University of Pennsylvania ("PENN") and the Children's Hospital of Philadelphia ("Children's Hospital")
B) CCA's Nanoscale Particle Complex (“NPC”) technology
C) a phospholipid-based nano-encapsulation drug delivery system
D) anti-cancer /general immunity modular pharmaceutical products and other pharmaceuticals (including oral, intra-nasal, and sublingual products (such as vaccines, anti-inflammatory products, analgesics, and anti-dementia, hepatic detoxification, and cardiovascular products) and topical products (such as anti-inflammatory products, analgesics, anti-infective agents (bacterial, viral and fungal) basal cell treatments and vaccines, and melanoma treatments and vaccines)).
E)Michael W Fountain
All answers can be found in government and public documents